Merrimack Pharmaceuticals Inc (MACK) 10.22 $MACK
Merrimack Pharmaceuticals Announces Timing of Fourth Quarter 2014 Investor Conference Call
GlobeNewswire - Thu Feb 12, 7:01AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Fourth Quarter 2014 Investor Conference Call and webcast at 8:30 a.m., Eastern time, on Thursday, February 26.
MACK: 10.22 (+0.40)
Biotech Stocks Technical Review -- Merrimack Pharma, Orexigen Therapeutics, Alkermes, Galena Biopharma, and Synta Pharma
PR Newswire - Wed Feb 11, 8:05AM CST
Editor Note: For more information about this release, please scroll to bottom.
MACK: 10.22 (+0.40), OREX: 5.55 (+0.10), SNTA: 2.29 (-0.03), GALE: 1.68 (+0.06), ALKS: 71.40 (-1.89)
Merrimack Pharmaceuticals Names Birgit M. Schoeberl, Ph.D. as Head of Discovery Division and Announces the Addition of Ulrik B. Nielsen, Ph.D. to Its Board of Directors
GlobeNewswire - Thu Jan 22, 4:00PM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Birgit M. Schoeberl, Ph.D. has been named the new head of its Discovery division. Ulrik B. Nielsen, Ph.D. will be stepping down as the head of the Discovery division and has been elected to serve on Merrimack's Board of Directors. Anthony J. Sinskey, Sc.D. will also be resigning from the Board of Directors and will continue as a scientific advisor. All of these transitions will occur on January 30, 2015.
MACK: 10.22 (+0.40)
Merrimack Reveals Additional Data from Oncology Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 2:20PM CST
Merrimack (MACK) announced additional analyses from the phase III NAPOLI-1 study on MM-398 .
MACK: 10.22 (+0.40), BAX: 70.39 (+0.31), ALXN: 182.29 (+6.02), RGDO: 1.17 (+0.02)
CAR-T Vs ErbB3 Market Opportunity Comparison
Decision Analytics - Seeking Alpha - Wed Jan 21, 12:32PM CST
CAR-T therapy, also known as "Adoptive Immunotherapy", has been the result of significant investor excitement recently. One look at the stock charts for JUNO and KITE is illustrative of this optimism. While this enthusiasm may be warranted,...
MACK: 10.22 (+0.40), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), BLCM: 20.00 (-0.81), KITE: 62.59 (+0.82), AVEO: 0.84 (-0.06), JUNO: 40.52 (+0.18), GSK: 47.94 (+1.99), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
PharmaEngine Announces Phase 2 PEPCOL Study Presented at the 2015 ASCO GI of PEP02 (MM-398) in Combination with 5-FU/LV in Unresectable Metastatic Colorectal Cancer
Business Wire - Wed Jan 21, 12:41AM CST
PharmaEngine, Inc. (TWO:4162) today announced that the data from the randomized non-comparative phase 2 PEPCOL study of PEP02 (MM-398, liposome irinotecan injection) in unresectable metastatic colorectal cancer (mCRC) were presented as a poster at the American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium (ASCO GI) on January 17, 2015. This PEPCOL study was sponsored by Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR) and co-sponsored by PharmaEngine and PharmaEngine's partner, Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK).
MACK: 10.22 (+0.40)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Jan 20, 4:38PM CST
MACK: 10.22 (+0.40), NFLX: 466.10 (+9.37), WWD: 48.59 (+0.11), ACTG: 13.13 (+0.04), NVAX: 8.80 (+0.40), CONN: 24.69 (-0.07), ILMN: 198.54 (+1.81), ARNA: 4.55 (+0.02), CREE: 37.51 (+0.08)
Merrimack Pharmaceuticals Presents Additional Analyses of Phase 3 MM-398 NAPOLI-1 Study at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium
GlobeNewswire - Tue Jan 20, 7:12AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced that additional analyses were presented on January 16, 2015 from the Phase 3 NAPOLI-1 study of MM-398 (irinotecan liposome injection), also known as "nal-IRI," in patients with metastatic pancreatic cancer previously treated with gemcitabine-based therapy. The data were presented by Li-Tzong Chen, M.D., Ph.D. in an oral session at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium in San Francisco, CA. Merrimack and Baxter International's biopharmaceutical business (NYSE:BAX) are collaborating on the development and commercialization of MM-398 outside of the United States and Taiwan. PharmaEngine, Inc. (Taipei, Taiwan) holds the rights to commercialize MM-398 in Taiwan. Additionally, Merrimack presented preclinical and clinical data from studies of its investigational agents MM-141 and MM-151 in pancreatic and colorectal cancer, respectively. An investigator-sponsored study of MM-398 in colorectal cancer was also presented.
MACK: 10.22 (+0.40), BAX: 70.39 (+0.31)
PharmaEngine Announces Expanded Analyses of Phase 3 MM-398 NAPOLI-1 Study Presented at the 2015 ASCO GI Substantiate the Positive Results of MM-398 in Combination with 5-FU/LV
Business Wire - Mon Jan 19, 3:00AM CST
PharmaEngine, Inc. (TWO: 4162) today announced that the additional analyses from the global phase 3 NAPOLI-1 study of MM-398 (PEP02, liposome irinotecan injection) in metastatic pancreatic cancer were presented by Li-Tzong Chen, M.D., Ph.D. in an oral session at the American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium (ASCO GI) on January 16, 2015. This phase 3 NAPOLI-1 study was sponsored by PharmaEngine's partner, Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK). PharmaEngine retains the rights to commercialize MM-398 in Taiwan.
MACK: 10.22 (+0.40), BAX: 70.39 (+0.31)
Technical Scrutiny on Biotech Stocks - Galena Biopharma, Synta Pharma, Merrimack Pharma, Vertex Pharma, and Spectrum Pharma
PR Newswire - Wed Jan 07, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Galena Biopharma Inc. (NASDAQ: GALE), Synta Pharmaceuticals Corporation (NASDAQ: SNTA), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, January 06, 2015, the NASDAQ Composite ended at 4,592.74, down 1.29%, the Dow Jones Industrial Average edged 0.74% lower, to finish the day at 17,371.64, and the S&P 500 closed at 2,002.61, down 0.89%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 788.11, down 0.27%, while the index has advanced 6.19% in the previous three months. Register for your complimentary reports on these five stocks at:
MACK: 10.22 (+0.40), VRTX: 113.66 (+4.03), SNTA: 2.29 (-0.03), SPPI: 7.20 (+0.15), GALE: 1.68 (+0.06)
Merrimack Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Wed Jan 07, 7:00AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy, President & CEO, is scheduled to present at the 33 Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2015 at 9:30 a.m. (PT) at the Westin St. Francis Hotel in San Francisco.
MACK: 10.22 (+0.40), JPM: 59.67 (+0.10)
Can the Rally in Merrimack Pharmaceuticals (MACK) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 7:21AM CST
Can the Rally in Merrimack Pharmaceuticals (MACK) Shares Continue?
MACK: 10.22 (+0.40)
Osteosarcoma - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/kjklc9/osteosarcoma) has announced the addition of the "Osteosarcoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteosarcoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Osteosarcoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Osteosarcoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Oncolytics Biotech Inc. - Med Discovery SA - Aileron Therapeutics, Inc. - Merrimack Pharmaceuticals, Inc. - Bellicum Pharmaceuticals, Inc. - Sutro Biopharma, Inc. - Eleison Pharmaceuticals, Inc. - Apoplogic Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/kj...teosarcoma
MACK: 10.22 (+0.40), ONCY: 0.51 (+0.02), BLCM: 20.00 (-0.81), GSK: 47.94 (+1.99)
Merrimack Pharmaceuticals Announces the Addition of Russell T. Ray to Its Board of Directors
GlobeNewswire - Wed Dec 17, 7:09AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the election of Russell T. Ray to its Board of Directors, effective January 1, 2015. Ray is a leading investment banker and venture capital investor in the life sciences sector, and has served as a director and advisor for many prominent companies in the healthcare sector during his 30 years of experience.
MACK: 10.22 (+0.40), AGN: 229.49 (+1.87), DB: 32.29 (+0.70)
Twitter's Favorite Biotech and Pharma Stocks
Brian Orelli, The Motley Fool - Motley Fool - Tue Dec 16, 8:21AM CST
Mark Schoenebaum, the biotech and pharmaceutical analyst at Evercore ISI, asked the Twittersphere for their favorite drug stocks going into next year. What's your favorite stock for 2015 in biotech or Pharma? — Mark Schoenebaum...
BLUE: 90.70 (+0.93), BMRN: 100.76 (+1.98), TGTX: 13.13 (-0.19), BMY: 60.04 (+0.56), MACK: 10.22 (+0.40), FMI: 48.88 (+0.17), RNA: 18.65 (unch), GWPH: 78.09 (+1.70), SRPT: 12.76 (+0.11), MRK: 58.81 (-0.07), NLNK: 38.84 (+1.51), ICPT: 209.12 (+7.12), THLD: 4.03 (+0.21), CEMP: 27.68 (+1.25), NVS: 102.20 (-0.17)
Ewing Sarcoma - Pipeline Review, H1 2014
M2 - Mon Dec 15, 3:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/l4jf65/ewing_sarcoma) has announced the addition of the "Ewing Sarcoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ewing Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ewing Sarcoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ewing Sarcoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ewing Sarcoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Shionogi & Co., Ltd. - Amgen Inc. - AstraZeneca PLC - Daiichi Sankyo Company, Limited - Sigma-Tau S.p.A. - Oncolytics Biotech Inc. - Merrimack Pharmaceuticals, Inc. - Pharma Mar, S.A. - EntreChem, S.L. For more information visit http://www.researchandmarkets.com/research/l4...ing_sarcom
MACK: 10.22 (+0.40), ONCY: 0.51 (+0.02), AZN: 69.96 (+0.20), AMGN: 153.48 (+0.30)
Merrimack Pharmaceuticals Presents Research on Innovative Pipeline for Patients With Breast Cancer at the 2014 San Antonio Breast Cancer Symposium
GlobeNewswire - Fri Dec 12, 7:04AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced data from multiple presentations at the 2014 San Antonio Breast Cancer Symposium in San Antonio, TX. Presentations include preclinical research and clinical data on MM-398, MM-302 and MM-121.
MACK: 10.22 (+0.40)
Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H1 2014
M2 - Thu Dec 11, 4:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/fqhvxz/gastroesophageal) has announced the addition of the "Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Gastroesophageal (GE) Junction Carcinomas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastroesophageal (GE) Junction Carcinomas and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Gastroesophageal (GE) Junction Carcinomas - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Gastroesophageal (GE) Junction Carcinomas pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche - Amgen - Gilead Sciences - Merck & Co - Millennium Pharmaceuticals - Merrimack Pharmaceuticals - Aslan Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/fq...esophageal
MACK: 10.22 (+0.40), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56)
Insider Trading Alert - UGI, NBS And MACK Traded By Insiders
at The Street - Fri Dec 05, 10:15AM CST
Stocks with insider trader activity include UGI, NBS and MACK
MACK: 10.22 (+0.40), UGI: 34.51 (-0.20), NBS: 3.78 (+0.14)
Video Release -- Preclinical Research Differentiating the Activity of Merrimack's MM-398, Nanoliposomal Irinotecan (nal-IRI), Published in Cancer Research
GlobeNewswire - Thu Dec 04, 7:06AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that Cancer Research has published the paper "Preclinical Activity of Nanoliposomal Irinotecan is Governed by Tumor Deposition and Intratumor Prodrug Conversion" in its latest issue (Volume 74, Issue 23).
MACK: 10.22 (+0.40), BAX: 70.39 (+0.31)
Merrimack Pharmaceuticals Announces Timing of Fourth Quarter 2014 Investor Conference Call
GlobeNewswire - Thu Feb 12, 7:01AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Fourth Quarter 2014 Investor Conference Call and webcast at 8:30 a.m., Eastern time, on Thursday, February 26.
MACK: 10.22 (+0.40)
Biotech Stocks Technical Review -- Merrimack Pharma, Orexigen Therapeutics, Alkermes, Galena Biopharma, and Synta Pharma
PR Newswire - Wed Feb 11, 8:05AM CST
Editor Note: For more information about this release, please scroll to bottom.
MACK: 10.22 (+0.40), OREX: 5.55 (+0.10), SNTA: 2.29 (-0.03), GALE: 1.68 (+0.06), ALKS: 71.40 (-1.89)
Merrimack Pharmaceuticals Names Birgit M. Schoeberl, Ph.D. as Head of Discovery Division and Announces the Addition of Ulrik B. Nielsen, Ph.D. to Its Board of Directors
GlobeNewswire - Thu Jan 22, 4:00PM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Birgit M. Schoeberl, Ph.D. has been named the new head of its Discovery division. Ulrik B. Nielsen, Ph.D. will be stepping down as the head of the Discovery division and has been elected to serve on Merrimack's Board of Directors. Anthony J. Sinskey, Sc.D. will also be resigning from the Board of Directors and will continue as a scientific advisor. All of these transitions will occur on January 30, 2015.
MACK: 10.22 (+0.40)
Merrimack Reveals Additional Data from Oncology Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 2:20PM CST
Merrimack (MACK) announced additional analyses from the phase III NAPOLI-1 study on MM-398 .
MACK: 10.22 (+0.40), BAX: 70.39 (+0.31), ALXN: 182.29 (+6.02), RGDO: 1.17 (+0.02)
CAR-T Vs ErbB3 Market Opportunity Comparison
Decision Analytics - Seeking Alpha - Wed Jan 21, 12:32PM CST
CAR-T therapy, also known as "Adoptive Immunotherapy", has been the result of significant investor excitement recently. One look at the stock charts for JUNO and KITE is illustrative of this optimism. While this enthusiasm may be warranted,...
MACK: 10.22 (+0.40), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), BLCM: 20.00 (-0.81), KITE: 62.59 (+0.82), AVEO: 0.84 (-0.06), JUNO: 40.52 (+0.18), GSK: 47.94 (+1.99), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
PharmaEngine Announces Phase 2 PEPCOL Study Presented at the 2015 ASCO GI of PEP02 (MM-398) in Combination with 5-FU/LV in Unresectable Metastatic Colorectal Cancer
Business Wire - Wed Jan 21, 12:41AM CST
PharmaEngine, Inc. (TWO:4162) today announced that the data from the randomized non-comparative phase 2 PEPCOL study of PEP02 (MM-398, liposome irinotecan injection) in unresectable metastatic colorectal cancer (mCRC) were presented as a poster at the American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium (ASCO GI) on January 17, 2015. This PEPCOL study was sponsored by Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR) and co-sponsored by PharmaEngine and PharmaEngine's partner, Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK).
MACK: 10.22 (+0.40)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Jan 20, 4:38PM CST
MACK: 10.22 (+0.40), NFLX: 466.10 (+9.37), WWD: 48.59 (+0.11), ACTG: 13.13 (+0.04), NVAX: 8.80 (+0.40), CONN: 24.69 (-0.07), ILMN: 198.54 (+1.81), ARNA: 4.55 (+0.02), CREE: 37.51 (+0.08)
Merrimack Pharmaceuticals Presents Additional Analyses of Phase 3 MM-398 NAPOLI-1 Study at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium
GlobeNewswire - Tue Jan 20, 7:12AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced that additional analyses were presented on January 16, 2015 from the Phase 3 NAPOLI-1 study of MM-398 (irinotecan liposome injection), also known as "nal-IRI," in patients with metastatic pancreatic cancer previously treated with gemcitabine-based therapy. The data were presented by Li-Tzong Chen, M.D., Ph.D. in an oral session at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium in San Francisco, CA. Merrimack and Baxter International's biopharmaceutical business (NYSE:BAX) are collaborating on the development and commercialization of MM-398 outside of the United States and Taiwan. PharmaEngine, Inc. (Taipei, Taiwan) holds the rights to commercialize MM-398 in Taiwan. Additionally, Merrimack presented preclinical and clinical data from studies of its investigational agents MM-141 and MM-151 in pancreatic and colorectal cancer, respectively. An investigator-sponsored study of MM-398 in colorectal cancer was also presented.
MACK: 10.22 (+0.40), BAX: 70.39 (+0.31)
PharmaEngine Announces Expanded Analyses of Phase 3 MM-398 NAPOLI-1 Study Presented at the 2015 ASCO GI Substantiate the Positive Results of MM-398 in Combination with 5-FU/LV
Business Wire - Mon Jan 19, 3:00AM CST
PharmaEngine, Inc. (TWO: 4162) today announced that the additional analyses from the global phase 3 NAPOLI-1 study of MM-398 (PEP02, liposome irinotecan injection) in metastatic pancreatic cancer were presented by Li-Tzong Chen, M.D., Ph.D. in an oral session at the American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium (ASCO GI) on January 16, 2015. This phase 3 NAPOLI-1 study was sponsored by PharmaEngine's partner, Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK). PharmaEngine retains the rights to commercialize MM-398 in Taiwan.
MACK: 10.22 (+0.40), BAX: 70.39 (+0.31)
Technical Scrutiny on Biotech Stocks - Galena Biopharma, Synta Pharma, Merrimack Pharma, Vertex Pharma, and Spectrum Pharma
PR Newswire - Wed Jan 07, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Galena Biopharma Inc. (NASDAQ: GALE), Synta Pharmaceuticals Corporation (NASDAQ: SNTA), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, January 06, 2015, the NASDAQ Composite ended at 4,592.74, down 1.29%, the Dow Jones Industrial Average edged 0.74% lower, to finish the day at 17,371.64, and the S&P 500 closed at 2,002.61, down 0.89%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 788.11, down 0.27%, while the index has advanced 6.19% in the previous three months. Register for your complimentary reports on these five stocks at:
MACK: 10.22 (+0.40), VRTX: 113.66 (+4.03), SNTA: 2.29 (-0.03), SPPI: 7.20 (+0.15), GALE: 1.68 (+0.06)
Merrimack Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Wed Jan 07, 7:00AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy, President & CEO, is scheduled to present at the 33 Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2015 at 9:30 a.m. (PT) at the Westin St. Francis Hotel in San Francisco.
MACK: 10.22 (+0.40), JPM: 59.67 (+0.10)
Can the Rally in Merrimack Pharmaceuticals (MACK) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 7:21AM CST
Can the Rally in Merrimack Pharmaceuticals (MACK) Shares Continue?
MACK: 10.22 (+0.40)
Osteosarcoma - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/kjklc9/osteosarcoma) has announced the addition of the "Osteosarcoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteosarcoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Osteosarcoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Osteosarcoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Oncolytics Biotech Inc. - Med Discovery SA - Aileron Therapeutics, Inc. - Merrimack Pharmaceuticals, Inc. - Bellicum Pharmaceuticals, Inc. - Sutro Biopharma, Inc. - Eleison Pharmaceuticals, Inc. - Apoplogic Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/kj...teosarcoma
MACK: 10.22 (+0.40), ONCY: 0.51 (+0.02), BLCM: 20.00 (-0.81), GSK: 47.94 (+1.99)
Merrimack Pharmaceuticals Announces the Addition of Russell T. Ray to Its Board of Directors
GlobeNewswire - Wed Dec 17, 7:09AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the election of Russell T. Ray to its Board of Directors, effective January 1, 2015. Ray is a leading investment banker and venture capital investor in the life sciences sector, and has served as a director and advisor for many prominent companies in the healthcare sector during his 30 years of experience.
MACK: 10.22 (+0.40), AGN: 229.49 (+1.87), DB: 32.29 (+0.70)
Twitter's Favorite Biotech and Pharma Stocks
Brian Orelli, The Motley Fool - Motley Fool - Tue Dec 16, 8:21AM CST
Mark Schoenebaum, the biotech and pharmaceutical analyst at Evercore ISI, asked the Twittersphere for their favorite drug stocks going into next year. What's your favorite stock for 2015 in biotech or Pharma? — Mark Schoenebaum...
BLUE: 90.70 (+0.93), BMRN: 100.76 (+1.98), TGTX: 13.13 (-0.19), BMY: 60.04 (+0.56), MACK: 10.22 (+0.40), FMI: 48.88 (+0.17), RNA: 18.65 (unch), GWPH: 78.09 (+1.70), SRPT: 12.76 (+0.11), MRK: 58.81 (-0.07), NLNK: 38.84 (+1.51), ICPT: 209.12 (+7.12), THLD: 4.03 (+0.21), CEMP: 27.68 (+1.25), NVS: 102.20 (-0.17)
Ewing Sarcoma - Pipeline Review, H1 2014
M2 - Mon Dec 15, 3:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/l4jf65/ewing_sarcoma) has announced the addition of the "Ewing Sarcoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ewing Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ewing Sarcoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ewing Sarcoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ewing Sarcoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Shionogi & Co., Ltd. - Amgen Inc. - AstraZeneca PLC - Daiichi Sankyo Company, Limited - Sigma-Tau S.p.A. - Oncolytics Biotech Inc. - Merrimack Pharmaceuticals, Inc. - Pharma Mar, S.A. - EntreChem, S.L. For more information visit http://www.researchandmarkets.com/research/l4...ing_sarcom
MACK: 10.22 (+0.40), ONCY: 0.51 (+0.02), AZN: 69.96 (+0.20), AMGN: 153.48 (+0.30)
Merrimack Pharmaceuticals Presents Research on Innovative Pipeline for Patients With Breast Cancer at the 2014 San Antonio Breast Cancer Symposium
GlobeNewswire - Fri Dec 12, 7:04AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced data from multiple presentations at the 2014 San Antonio Breast Cancer Symposium in San Antonio, TX. Presentations include preclinical research and clinical data on MM-398, MM-302 and MM-121.
MACK: 10.22 (+0.40)
Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H1 2014
M2 - Thu Dec 11, 4:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/fqhvxz/gastroesophageal) has announced the addition of the "Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Gastroesophageal (GE) Junction Carcinomas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastroesophageal (GE) Junction Carcinomas and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Gastroesophageal (GE) Junction Carcinomas - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Gastroesophageal (GE) Junction Carcinomas pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche - Amgen - Gilead Sciences - Merck & Co - Millennium Pharmaceuticals - Merrimack Pharmaceuticals - Aslan Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/fq...esophageal
MACK: 10.22 (+0.40), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56)
Insider Trading Alert - UGI, NBS And MACK Traded By Insiders
at The Street - Fri Dec 05, 10:15AM CST
Stocks with insider trader activity include UGI, NBS and MACK
MACK: 10.22 (+0.40), UGI: 34.51 (-0.20), NBS: 3.78 (+0.14)
Video Release -- Preclinical Research Differentiating the Activity of Merrimack's MM-398, Nanoliposomal Irinotecan (nal-IRI), Published in Cancer Research
GlobeNewswire - Thu Dec 04, 7:06AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that Cancer Research has published the paper "Preclinical Activity of Nanoliposomal Irinotecan is Governed by Tumor Deposition and Intratumor Prodrug Conversion" in its latest issue (Volume 74, Issue 23).
MACK: 10.22 (+0.40), BAX: 70.39 (+0.31)
